Mölndal, Sweden

Staffan Po Karlsson

USPTO Granted Patents = 15 


 

Average Co-Inventor Count = 9.8

ph-index = 4

Forward Citations = 61(Granted Patents)


Location History:

  • Molndal, SE (2011)
  • Mölndal, SE (2011 - 2024)

Company Filing History:


Years Active: 2011-2024

Loading Chart...
Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents

Title: **The Innovations of Staffan Po Karlsson: A Focused Inventor in Pharmaceutical Research**

Introduction

Staffan Po Karlsson, located in Mölndal, Sweden, is a distinguished inventor with an impressive portfolio comprising 15 patents. His work primarily focuses on pharmaceutical innovations aimed at addressing significant health challenges, particularly in respiratory medicine.

Latest Patents

Among his latest contributions to the field are two pivotal patents regarding certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides. These compounds have been identified as dipeptidyl peptidase 1 (DPP1) inhibitors. The significance of these inventions lies in their potential utility for treating and preventing clinical conditions, including respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Karlsson's work encompasses their therapeutic applications, the formulation of pharmaceutical compositions containing these compounds, and the processes involved in their preparation.

Career Highlights

Staffan Po Karlsson is currently affiliated with AstraZeneca AB, a leading global biopharmaceutical company known for its commitment to innovation in drugs and therapies. His ongoing research and development efforts are integral to AstraZeneca's mission to advance healthcare solutions.

Collaborations

Throughout his career, Karlsson has collaborated with esteemed colleagues including Stephen Connolly and Steven Swallow. These collaborations have facilitated the exchange of ideas and have enhanced the impact of his innovations in the pharmaceutical industry.

Conclusion

Staffan Po Karlsson exemplifies the role of an innovative inventor in the realm of pharmaceutical development. His contributions, particularly in the formulation of DPP1 inhibitors, underscore the importance of research and patenting in addressing complex health issues. With a strong foundation in collaboration and a commitment to improving patient care, Karlsson continues to be a valuable asset to the scientific community and the broader field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…